Efficacy of alfuzosine (an alpha 1-adrenoreceptor blocking drug) in benign hyperplasia of the prostate.
Thirty-three patients with symptoms of outflow obstruction due to BPH were randomized into a double-blind study for 8 weeks treatment with alfuzosine 2.5 mg x 3 or placebo. Alfuzosine blood concentrations were analysed. The residual volume was significantly reduced in the alfuzosine group, from 98 to 43 cc (p less than 0.02) and the average urinary flow as measured by timed micturition was significantly improved (p = 0.023). Subjective symptoms were reduced in both groups. However, no statistically significant differences between the groups were recorded. Side-effects were limited and without clinical importance.
Carbin
B E
BE
Department of Urology, Karolinska Hospital, Vällingby, Stockholm, Sweden.
Bauer
P
P
Friskand
M
M
Moyse
D
D
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000368:Aged; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011799:Quinazolines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; C047638:alfuzosin